skip to content
Primary navigation


DrugNinlaro® (ixazomib) [Millennium Pharmaceuticals, Inc.]

May 2016

Therapeutic area - Oncology

Approval criteria

  • Patient must be 18 years of age or older AND
  • Have a diagnosis of multiple myeloma AND
  • Must be prescribed in combination with lenalidomide and dexamethasone AND
  • Patient has had at least one prior treatment for multiple myeloma AND
  • Patient has not had prior therapy with lenalidomide or proteasome inhibitors AND
  • If female, patient is not pregnant or planning to become pregnant and should be advised to avoid pregnancy for 90 days following the final dose of Ninlaro

Quantity limit

Maximum of 3 capsules per 28 days


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top